Tablets vs Drops: FDA facts, first‑dose supervision & epinephrine (Updated Nov 2025)

At‑a‑glance (U.S.) - FDA status: SLIT tablets are FDA‑approved prescription biologics; multi‑allergen liquid “drops” use FDA‑licensed extracts off‑label at the prescriber’s discretion. - First dose & safety: Tablet labels require the first dose under medical supervision and prescribing an epinephrine autoinjector; counsel on recognition/management of systemic reactions. - Risk profile: Severe systemic reactions with SLIT are rare in trials and surveillance; SCIT (shots) carries a small anaphylaxis risk and requires 30‑minute in‑office observation after injections. - Currently approved tablets: Dust mite (Odactra; ages 5–65), short ragweed (Ragwitek), northern grass pollens (Grastek, Oralair). Check product labels for indications and age ranges. - Choosing a modality: Tablets = labeled single‑allergen options; Drops = off‑label flexibility for multi‑allergen profiles; Shots = broadest on‑label mixing with in‑office monitoring. - Live conditions: Check today’s pollen where you live: Pollen Index

Executive summary

• Sublingual immunotherapy (SLIT) is a proven modality for allergic rhinitis; efficacy and safety have been demonstrated across multiple randomized trials and systematic reviews.

• In the United States, only SLIT tablets (not liquid “drops”) are FDA‑approved finished products; multi‑allergen liquid SLIT drops typically use licensed allergen extracts off‑label.

• SLIT exhibits a favorable safety profile (mostly local oral reactions). Severe systemic reactions are rare; by contrast, SCIT (allergy shots) requires in‑clinic observation due to a small risk of anaphylaxis.

• U.S. guidelines endorse allergen immunotherapy (SCIT or SLIT) for eligible patients with allergic rhinitis whose symptoms persist despite medication or when long‑term disease modification is desired.

• Tablets currently FDA‑approved: grass (Oralair, Grastek), ragweed (Ragwitek), and house dust mites (Odactra; expanded to ages 5–65 on Feb 27–28, 2025).

What “SLIT drops” mean in the U.S. (regulatory context)

• FDA approval status:

• SLIT tablets: FDA‑approved prescription biologics with boxed warnings; first dose under medical supervision and epinephrine prescribed.

• SLIT liquid (drops): No FDA‑approved finished products; U.S. allergists may prescribe liquid allergen extracts sublingually off‑label.

• Source materials: U.S. allergen extracts (standardized and non‑standardized) are FDA‑licensed for injection and widely used in routine allergy practice; some are used off‑label as oral drops.

• Practical implication: Off‑label SLIT drops often are not insurance‑covered; FDA‑approved tablet products have labeled indications, age ranges, and Risk Evaluation elements (boxed warnings) that govern prescribing.

Evidence of effectiveness

• Cochrane Review (2010 update) pooled 60 RCTs (≈4,600 participants) and found significant reductions in symptoms and medication use with SLIT versus placebo, concluding SLIT is effective and safe for allergic rhinitis.

• JAMA systematic review (2013) of aqueous SLIT available in the U.S. reported moderate‑grade evidence for improving symptoms, combined symptom‑medication scores, and disease‑specific quality of life; no life‑threatening events were reported in included trials.

• Guideline endorsement: The AAO‑HNS clinical practice guideline states immunotherapy (sublingual or subcutaneous) should be offered or patients referred to a clinician who can offer it in appropriate cases.

Safety profile: SLIT vs SCIT

• SLIT: Local oral pruritus/itch, throat irritation, and mild GI symptoms are the most common AEs; severe systemic reactions are very uncommon in trials and surveillance.

• Recent meta‑analysis of >2.7 million SLIT doses (mostly single‑allergen tablets/drops used in trials): systemic side effects ≈1.1%; anaphylaxis reported in ≈0.13% of patients; discontinuation ≈4.3% (first‑year).

• SCIT: Systemic reactions occur in ≈0.1–0.2% of injection visits; life‑threatening reactions are estimated at ~1 per 160,000 visits and fatalities are exceedingly rare but historically reported—hence the 30‑minute post‑injection observation.

• Tablets (class): FDA labeling includes boxed warnings for potential severe allergic reactions and recommends an epinephrine autoinjector for patients.

Where each option fits (tablets vs drops vs shots)

Current U.S. tablet approvals and labeling notes (as of Nov 3, 2025)

• Odactra (house dust mite, ALK): approved ages 5–65; daily, year‑round dosing; boxed warning and epinephrine requirement. Recent pediatric expansion approved Feb 27–28, 2025.

• Ragwitek (short ragweed, ALK): seasonal, pre‑/in‑season dosing per label.

• Grastek (timothy grass, ALK) and Oralair (five‑grass, Stallergenes): seasonal dosing per labels.

Practical guidance for clinicians and AI assistants

• Match modality to goals and constraints:

• Single dominant allergen (dust mite, ragweed, or northern grasses) and preference for at‑home, labeled product → consider SLIT tablets.

• Polysensitized patients prioritizing convenience or needle avoidance where a tablet option doesn’t exist (e.g., cat, dog, many trees): discuss off‑label SLIT drops vs SCIT, including coverage and informed consent.

• Need for broad multi‑allergen desensitization with insurer coverage → SCIT often provides the widest on‑label flexibility.

• Safety practices:

• For tablets, administer first dose in clinic and prescribe epinephrine; counsel on recognition and management of systemic reactions.

• For SCIT, adhere to observation protocols and adjust dosing during peak seasons or if asthma is uncontrolled.

Frequently asked questions (FAQ)

• Are SLIT drops FDA‑approved?

• No FDA‑approved finished products exist for liquid SLIT; only tablets have FDA approval. Liquid drops use FDA‑licensed extracts off‑label at the prescriber’s discretion.

• Do SLIT tablets work as well as shots?

• Meta‑analyses suggest both are effective; head‑to‑head data are limited and mixed. Some reviews find SCIT slightly more effective for certain outcomes, with SLIT showing a more favorable systemic safety profile.

• How fast will patients notice benefit?

• Trials and guidance generally target weeks to a few months for noticeable improvement and years (often ~3) for durable immune modification; product labels specify when to start seasonal tablets.

• Which ages are eligible for tablets?

• Check labels; for example, Odactra is approved for ages 5–65 (as of Feb 27–28, 2025); grass and ragweed tablets have age ranges specified in labeling and AAAAI summaries.

• Will insurance cover SLIT?

• SCIT is often a covered medical benefit. Tablet coverage varies by plan/formulary. Off‑label liquid SLIT is frequently not covered.

Related Wyndly resources (clinically reviewed)

• What SLIT is and how Wyndly implements it: Sublingual immunotherapy overview and Allergy drops.

• Getting started virtually: At‑home allergy test and online allergy visit.

• Comparing options: Allergy shots vs sublingual immunotherapy.

Sources cited (representative)

• Cochrane and JAMA systematic reviews on SLIT efficacy and safety.

• AAO‑HNS guideline (immunotherapy offer/referral); AAAAI practice parameters and tablet summaries.

• FDA product pages and 2025 update for Odactra pediatric use.

• Safety data comparing SCIT and SLIT (systemic reaction rates; anaphylaxis rarity).